@mjphennig.bsky.social
Reposted
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.
annalsofoncology.org
May 20, 2025 at 6:16 PM
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study
annalsofoncology.org/article/S092...
annalsofoncology.org/article/S092...
Reposted
Association of the circulating lipid panel, PCPro, with clinical outcomes
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304).
Enzalutamide significantly improves overall survival (OS) of patients with metastatic
hormone- sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within
2 years. PCPro is a plasma l...
www.annalsofoncology.org
May 23, 2025 at 2:38 PM
Association of the circulating lipid panel, PCPro, with clinical outcomes
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
www.annalsofoncology.org/article/S092...
post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer
Reposted
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
FDA expands Pluvicto’s prostate cancer indication
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).
www.fda.gov
March 31, 2025 at 8:50 AM
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
www.fda.gov/drugs/resour...
FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
Reposted
As doctors, researchers, and other academics flee X (formerly Twitter), @munkeatlooi.bsky.social looks at what the social network Bluesky is and why #MedSky might be worth trying
www.bmj.com/content/388/...
www.bmj.com/content/388/...
February 27, 2025 at 12:57 PM
As doctors, researchers, and other academics flee X (formerly Twitter), @munkeatlooi.bsky.social looks at what the social network Bluesky is and why #MedSky might be worth trying
www.bmj.com/content/388/...
www.bmj.com/content/388/...
Reposted
Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
February 15, 2025 at 5:21 PM
Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
✅ PFS & OS benefit in all groups
✅ Benefit in cisplatin eligible/ineligible
✅ Safety consistent with prior analysis
✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social
Reposted
"addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer." #gu25
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicen...
The addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival
and some aspects of HRQOL in patients with high-risk metastatic castration-resistant
prostate cancer. Our find...
www.thelancet.com
February 14, 2025 at 3:01 AM
"addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer." #gu25
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Reposted
These are the 2 key slides from the #Talapro2 presentation @asco #GU25
Where HR crosses 1.0 in pts w/no known
HRR mutation status & Gd3 toxicity difference of 75% vs 45%
I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer
Where HR crosses 1.0 in pts w/no known
HRR mutation status & Gd3 toxicity difference of 75% vs 45%
I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer
February 13, 2025 at 5:30 PM
These are the 2 key slides from the #Talapro2 presentation @asco #GU25
Where HR crosses 1.0 in pts w/no known
HRR mutation status & Gd3 toxicity difference of 75% vs 45%
I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer
Where HR crosses 1.0 in pts w/no known
HRR mutation status & Gd3 toxicity difference of 75% vs 45%
I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer
Reposted
🔵1 in 3 men experience PSA persistence or relapse within 10 years post-radical prostatectomy.
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
January 20, 2025 at 7:13 PM
🔵1 in 3 men experience PSA persistence or relapse within 10 years post-radical prostatectomy.
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social
🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%).
🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology
@oncoalert.bsky.social